齐拉西酮与喹硫平治疗精神分裂症的对照研究

A comparative study of ziprasidone and quetiapine in the treatment of schizophren

目的探讨齐拉西酮对精冲分裂症的临床疗效及安全性。方法分析61例用齐拉西酮治疗8周的精神分裂症病例,并用61例喹硫平治疗精神分裂病例作对照。采用阳性及阴性症状量表(PANSS)的减分率评价疗效,用副反应量表(TESS)评价8周的副反应。结果治疗后,两组患者PANSS评分均明显下降,两组之间无显著性差异(P>0.05),但齐拉西酮组的副反应发生率低于喹硫平组,但差异无显著性,两组药物引起的副反应均为轻度和中度,表现有所不同,患者耐受性好。结论两药治疗精冲分裂症均有明确疗效,且安全性相对较高,齐拉西酮对症状的改善可能更好。

Objective To explore the clinical efficacy and saiety ot ziprasidone and quetlaplne in me treatment of schizophrenia. Methods 61 schizophrea inpatients were treated with ziprasidone for 8 weeks, and were compared with other 61 schizophrenia inpatients treated with quetapine clinical efficacy was measured （PANSS） and the side effects by （TESS）. Results After treatment the scores of（PANSS） in both groups decreased, but there were no statistical difference between two groups （ P 〉 0. 05 ）. However, ziprasi done took into effect more quickly, significant difference was found beween two groups in the reduction rate of scale about negative symploms （ P 〉 0. 05 ）. The side effects of ziprasidone were lower than those of quetiapine, but the difference was not significant. The tolerance of suffers was better and the oppearance side effects varied. Conclusion h is suggested that both drugs are effective exactly in the treatment of schizophrenic patients and fewer side effects, ziprasidon appeare to be more effective in improving psychiatric symtoms.